RK-251 — “Smart” Cancer Drug

• Indian Innovation: Indian researchers have developed RK-251, an experimental “smart” cancer drug designed to become active mainly inside cancer cells.
• Developed by: Collaborative research led by scientists from Institute of Advanced Study in Science and Technology (IASST) and IIT-Guwahati.
• Target: It has shown promising activity against triple-negative breast cancer (TNBC) in preclinical studies.

How Does RK-251 Work?

• Prodrug: RK-251 is designed as a prodrug, meaning it becomes pharmacologically active after a specific trigger.
• Trigger — ROS: Cancer cells often have higher levels of Reactive Oxygen Species (ROS) than normal cells.
• Selective Activation: RK-251 responds to the high-ROS environment inside cancer cells.
• Release of NBDHEX: Once activated, it releases NBDHEX, an anticancer compound.
• Target: NBDHEX inhibits GSTP1, a protein associated with cancer-cell survival and resistance mechanisms.
• Objective: The approach aims to reduce damage to healthy cells compared with conventional chemotherapy.

Theranostic Feature

• Fluorescent Component: RK-251 incorporates a near-infrared fluorescent component.
• Dual Function: It combines therapy + diagnostic monitoring, a concept known as a theranostic approach.
• Activation Signal: Fluorescence can indicate activation of the drug in an ROS-rich environment.

Preclinical Findings

• Triple-Negative Breast Cancer: RK-251 showed strong activity against aggressive TNBC cells in laboratory studies.
• Healthy Cells: It showed substantially lower effects on healthy cells under the tested conditions.
• Zebrafish Model: Studies using zebrafish embryos (Danio rerio) found no obvious signs of acute toxicity and demonstrated the expected fluorescence response.
• Current Status: Preclinical stage — it has not yet been established as a human treatment and requires further safety and efficacy testing.

Exam Trap: RK-251 is not yet a proven replacement for chemotherapy. It is an experimental candidate undergoing preclinical evaluation.

UPSC Prelims Practice Question — English

Q. With reference to RK-251, recently in news, consider the following statements:

1. It is a ROS-responsive prodrug designed to become active mainly inside cancer cells.
2. It releases NBDHEX upon activation.
3. It has already completed human clinical trials and replaced chemotherapy for triple-negative breast cancer.
4. Its development involves researchers from IASST and IIT-Guwahati.

Which of the statements given above are correct?

(a) 1, 2 and 4 only
(b) 1 and 3 only
(c) 2, 3 and 4 only
(d) 1, 2, 3 and 4

Answer: (a) 1, 2 and 4 only

Explanation

• 1 — Correct: RK-251 is designed to respond to elevated ROS levels in cancer cells.
• 2 — Correct: Activation releases NBDHEX.
• 3 — Incorrect: It remains at the preclinical stage.
• 4 — Correct: The research involved IASST and IIT-Guwahati.